New drug mix would simplify HIV therapy
Article Abstract:
While the current AIDS "drug cocktail" treatment program for HIV-infected patients requires taking from 10 to 20 pills a day, two companies have introduced new products to greatly reduce the number of pills per day required for effective treatment of HIV. Dupont Co. has developed a new, still unapproved drug called Sustiva that can be taken as one pill once a day. Glaxo Wellcome PLC has developed a new twice a day pill that combines both AZT and 3TC. The Dupont once-a-day pill can be taken with the Glaxo twice-a-day pill to create what researchers say is a combination that can counter HIV as well as or better than the current cocktail mix.
Comment:
Dupont introduces a new anti-HIV drug that need be taken only once a day
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Johnson & Johnson drug may pose risks
Article Abstract:
The Food and Drug Administration (FDA) regulators warned that a popular heartburn drug called Propulsid, manufactured by Johnson & Johnson, may cause potentially deadly heart-rhythm problems when taken in combination with other medications. The FDA recommended that the drug be taken only after all other options have failed, and included a list of other drugs that should not be taken with Propulsid. Based in New Brunswick, NJ, Johnson & Johnson will feel the impact of the FDA warning because Propulsid is one of the company's top-selling drugs, with sales of over $1 billion in 1997.
Comment:
FDA warns popular heartburn drug, Propulsid by Johnson & Johnson, may cause potentially deadly heart-rhythm problems
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Genentech earnings jump 70% on launch of lymphoma drug
Article Abstract:
Genentech Inc. announced that its net income for the second-quarter of 1998 improved 70% to $40.4 million. The improved net income was a reflection of the launch of Genentech's new Rituxan lymphoma drug. The company posted $23.8 million in quarterly earnings in 1997. Its revenue increased 15% for the quarter to $268 million. Rixutan sales fell slightly in the quarter to $34.8 million.
Comment:
Announced that its net income for the second-quarter of 1998 improved 70% to $40.4 million
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Accruals quality and internal control over financial reporting. Measuring reporting conservatism
- Abstracts: Computing returns the feel-good way. A new language may ease Web use. You are not alone: trial by CD-ROM
- Abstracts: Tough times in the video trade. Outsourced employment agency has a big job ahead of it. Insurer goes directly for the good risks
- Abstracts: GST promises to keep the industry on its toes. CEOs give coalition a qualified tick
- Abstracts: GM recalls nearly a million cars, citing a problem with air bags